1. Mechanisms and prediction of short-term natriuretic effect of sodium-glucose cotransporter 2 inhibitor in heart failure patients coexisting type 2 diabetes mellitus
- Author
-
Masaki Ishiyama, Naoki Fujimoto, Tetsushiro Takeuchi, Taku Omori, Kaoru Dohi, Shusuke Fukuoka, Masaaki Ito, and Keishi Moriwaki
- Subjects
Male ,medicine.medical_specialty ,Time Factors ,medicine.drug_class ,medicine.medical_treatment ,Urology ,Natriuresis ,Thiophenes ,Urine ,030204 cardiovascular system & hematology ,Urine sodium ,Excretion ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Glucosides ,Sodium Potassium Chloride Symporter Inhibitors ,Diabetes mellitus ,medicine ,Humans ,Prospective Studies ,030212 general & internal medicine ,Sodium-Glucose Transporter 2 Inhibitors ,Aged ,Aged, 80 and over ,Heart Failure ,business.industry ,Middle Aged ,Loop diuretic ,medicine.disease ,Hospitalization ,Treatment Outcome ,Ipragliflozin ,Diabetes Mellitus, Type 2 ,chemistry ,Heart failure ,Female ,Natriuretic Agents ,Diuretic ,Cardiology and Cardiovascular Medicine ,business - Abstract
The mechanisms of the diuretic effect of sodium-glucose cotransporter 2 (SGLT2) inhibitor and its predictors in heart failure (HF) patients with coexisting type 2 diabetes mellitus (T2DM) remain under investigation. A total of 40 hospitalized HF patients with T2DM (68 ± 13 years old, male gender 63%) were prospectively enrolled and received ipragliflozin at a dose of 50 mg once daily after breakfast for at least 4 consecutive days. They underwent first-morning blood and urine tests, and 24-h urine tests before and after short-term ipragliflozin therapy. Daily urine volume significantly increased from 1365 ± 511 mL/day on day 0 to 1698 ± 595 mL/day on day 3 (P
- Published
- 2020